ICON plc Stock Earnings Reports
ICON plc Earnings Calls
Release date | Apr 30, 2025 |
EPS estimate | $3.08 |
EPS actual | $3.19 |
EPS Surprise | 3.57% |
Revenue estimate | 2.041B |
Revenue actual | 2.001B |
Revenue Surprise | -1.95% |
Release date | Feb 19, 2025 |
EPS estimate | $3.41 |
EPS actual | $3.43 |
EPS Surprise | 0.587% |
Revenue estimate | 2.036B |
Revenue actual | 2.041B |
Revenue Surprise | 0.245% |
Release date | Oct 23, 2024 |
EPS estimate | $3.85 |
EPS actual | $3.35 |
EPS Surprise | -12.99% |
Revenue estimate | 2.036B |
Revenue actual | 2.03B |
Revenue Surprise | -0.307% |
Release date | Jul 24, 2024 |
EPS estimate | $3.68 |
EPS actual | $3.75 |
EPS Surprise | 1.90% |
Revenue estimate | 2.137B |
Revenue actual | 2.12B |
Revenue Surprise | -0.790% |
Last 4 Quarters for ICON plc
Below you can see how ICLR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Jul 24, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $331.77 |
EPS estimate | $3.68 |
EPS actual | $3.75 |
EPS surprise | 1.90% |
Date | Price |
---|---|
Jul 18, 2024 | $327.80 |
Jul 19, 2024 | $329.70 |
Jul 22, 2024 | $339.93 |
Jul 23, 2024 | $332.23 |
Jul 24, 2024 | $331.77 |
Jul 25, 2024 | $313.10 |
Jul 26, 2024 | $323.46 |
Jul 29, 2024 | $329.33 |
Jul 30, 2024 | $330.51 |
4 days before | 1.21% |
4 days after | -0.380% |
On release day | -5.63% |
Change in period | 0.83% |
Release date | Oct 23, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $280.76 |
EPS estimate | $3.85 |
EPS actual | $3.35 |
EPS surprise | -12.99% |
Date | Price |
---|---|
Oct 17, 2024 | $295.24 |
Oct 18, 2024 | $297.72 |
Oct 21, 2024 | $288.64 |
Oct 22, 2024 | $283.49 |
Oct 23, 2024 | $280.76 |
Oct 24, 2024 | $221.73 |
Oct 25, 2024 | $220.47 |
Oct 28, 2024 | $230.50 |
Oct 29, 2024 | $232.40 |
4 days before | -4.90% |
4 days after | -17.22% |
On release day | -21.03% |
Change in period | -21.28% |
Release date | Feb 19, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $191.32 |
EPS estimate | $3.41 |
EPS actual | $3.43 |
EPS surprise | 0.587% |
Date | Price |
---|---|
Feb 12, 2025 | $186.53 |
Feb 13, 2025 | $182.64 |
Feb 14, 2025 | $186.21 |
Feb 18, 2025 | $188.65 |
Feb 19, 2025 | $191.32 |
Feb 20, 2025 | $201.84 |
Feb 21, 2025 | $201.39 |
Feb 24, 2025 | $199.15 |
Feb 25, 2025 | $197.50 |
4 days before | 2.57% |
4 days after | 3.23% |
On release day | 5.50% |
Change in period | 5.88% |
Release date | Apr 30, 2025 |
Fiscal end date | Mar 31, 2025 |
Price on release | $151.44 |
EPS estimate | $3.08 |
EPS actual | $3.19 |
EPS surprise | 3.57% |
Date | Price |
---|---|
Apr 24, 2025 | $145.92 |
Apr 25, 2025 | $144.96 |
Apr 28, 2025 | $145.00 |
Apr 29, 2025 | $149.31 |
Apr 30, 2025 | $151.44 |
May 01, 2025 | $145.21 |
May 02, 2025 | $142.96 |
May 05, 2025 | $143.02 |
May 06, 2025 | $135.10 |
4 days before | 3.78% |
4 days after | -10.79% |
On release day | -4.11% |
Change in period | -7.42% |
ICON plc Earnings Call Transcript Summary of Q1 2025
Here's a summary of the key points from the ICON plc Q1 2025 earnings call that investors should note:
Market Overview:
- Cautious Optimism: ICON's management expressed cautious optimism due to mixed indicators in the biotech and large pharma sectors, highlighting a dynamic market environment with elevated cancellations and delays in clinical trials.
- Mixed Demand: Large pharma demand remains inconsistent, influenced by regulatory issues and budget constraints, while mid-sized pharma shows more potential.
- Increased Opportunities in Biotech: There is a notable increase in opportunities in the biotech sector, although cancellations and funding uncertainties persist.
Financial Performance:
- Revenue: Q1 revenue was $2 billion, a decrease of 4.3% year-on-year (3.2% on a constant currency basis).
- Bookings Performance: The book-to-bill ratio was 1.01, indicating some challenges with project bookings due to elevated cancellations, particularly in the biotech sector.
- Adjusted EBITDA Margin: The adjusted EBITDA margin was 19.5%, slightly better than expectations, showcasing effective cost management.
Cancellations & Guidance:
- Elevated Cancellations: The company saw elevated cancellation rates, affecting revenue forecasts. Cancellations stemmed from project prioritization and clinical decisions.
- Updated Guidance: ICON lowered its full-year revenue guidance by $400 million, with $350 million attributed to canceled COVID-related studies.
Operational & Strategic Focus:
- Cost Management: ICON is focusing on aligning resources and enhancing efficiencies through operational best practices and automation.
- Investment in AI Tools: The company released two AI-enabled tools to streamline trial processes, reflecting ongoing investments in technology to improve service delivery.
- Share Repurchase Strategy: ICON repurchased $250 million in shares during Q1 and plans to continue buying back shares as part of its capital deployment strategy while considering M&A opportunities.
Customer Relationships:
- Stable Trends with Major Customers: The company is seeing some downtick with its largest customers, but remains confident in its strategic partnerships and the ability to secure new wins.
- Market Dynamics in China: ICON expects growth opportunities from the expanding clinical trial capabilities in China, bolstered by its established presence in the region.
Conclusion:
ICON management remains proactive in navigating current market challenges, focusing on cost efficiency, strategic investments, and enhancing operational effectiveness. The ongoing investor focus should be on how these strategies will position ICON for sustained growth despite the backdrop of uncertainty in the biotech and pharma markets.